Clinical trial
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT00326625 is registered in ClinicalTrials.gov with Teva Pharmaceutical Industries, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Teva Pharmaceutical Industries, Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 27, 2006
- Completion date
- June 17, 2008
- Enrollment
- 366 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.